---
title: "Cocrystal Pharma Shareholders Approve Governance and Oversight Measures"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293036520.md"
description: "Cocrystal Pharma shareholders approved governance measures at the July 14, 2026 annual meeting, electing five directors and ratifying Weinberg & Company as auditor. While analyst ratings suggest a Buy with a $10 target, TipRanks' AI Spark rates COCP as Neutral due to weak financials and bearish technicals. The company remains focused on antiviral therapies."
datetime: "2026-07-17T12:28:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293036520.md)
  - [en](https://longbridge.com/en/news/293036520.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293036520.md)
generator: "portal-rs"
---

# Cocrystal Pharma Shareholders Approve Governance and Oversight Measures

Cocrystal Pharma ( (COCP) ) has provided an update.

On July 14, 2026, Cocrystal Pharma, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders voted on key governance and oversight matters. The meeting covered the election of board members, ratification of the independent auditor for the 2026 fiscal year and a contingency proposal to adjourn the meeting if more proxy solicitation were needed.

Stockholders elected five directors, including Dr. Roger Kornberg and Dr. Phillip Frost, to serve until the next annual meeting, reinforcing continuity in the company’s leadership. They also overwhelmingly ratified Weinberg & Company as the independent registered public accounting firm for the year ending December 31, 2026, ensuring stability in financial oversight, while the adjournment proposal became moot because the first two items received sufficient support.

The most recent analyst rating on (COCP) stock is a Buy  
 with a $10.00 price target.  
 To see the full list of analyst forecasts on Cocrystal Pharma stock,  
 see the COCP Stock Forecast page. 

**Spark’s Take on COCP Stock**

According to Spark, TipRanks’ AI Analyst, COCP is a Neutral.

The score is held down primarily by weak financial fundamentals (no revenue, ongoing losses and cash burn with funding dependence) and bearish technicals (below major moving averages with negative MACD). Positive pipeline/regulatory corporate events provide some support, but not enough to outweigh near-term financial and price-trend risk.

To see Spark’s full report on COCP stock,  
 click here. 

**More about Cocrystal Pharma**

Cocrystal Pharma, Inc. is a biotechnology company focused on developing antiviral therapies using structure-based drug design. Its research-driven business targets infectious diseases, positioning the company within the pharmaceutical and life sciences sector and aligning it with investors interested in innovative antiviral treatments.

The company’s market focus centers on advancing clinical and preclinical antiviral candidates, aiming to capture opportunities in segments such as influenza, coronavirus and other high-need viral indications. This specialization places Cocrystal in a competitive niche of the biopharmaceutical industry, where regulatory milestones and governance decisions are closely watched by stakeholders.

**Average Trading Volume:** 103,245

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** $13.24M

### Related Stocks

- [COCP.US](https://longbridge.com/en/quote/COCP.US.md)

## Related News & Research

- [CoreWeave AI Growth Comes With More Than $35 Billion in Debt](https://longbridge.com/en/news/303108283.md)
- [Verizon CEO Says SpaceX May Be Years Away From Becoming America's 'Sixth' Wireless Competitor](https://longbridge.com/en/news/303109070.md)
- [Micron Suffers a 99.8% Snub From Its Union, Exposing AI's Human Fault Line](https://longbridge.com/en/news/303110941.md)
- [AppLovin Corporation $APP Stock Purchased by Hedeker Wealth LLC](https://longbridge.com/en/news/303049441.md)
- [I'd Buy Half a Position in Amazon Stock Before Its Oct. 29 Report -- and Half After](https://longbridge.com/en/news/303054275.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**